Announcements Trials

Browse Landscape

Status

Recruiting 13 Completed 12 Terminated 6 Unknown 4 Active not recruiting 4 Withdrawn 1 Enrolling by invitation 1

Sponsor Class

Study Type

Observational 1

Sponsor

Conditions

Breast Neoplasms 438 Neoplasms 322 Carcinoma, Non-Small-Cell Lung 250 Prostatic Neoplasms 240 Lung Neoplasms 176 Colorectal Neoplasms 158 Pancreatic Neoplasms 148 Neoplasm Metastasis 142 Leukemia, Myeloid, Acute 140 Multiple Myeloma 131 Lymphoma 128 Carcinoma, Hepatocellular 127 Ovarian Neoplasms 109 Melanoma 109 Head and Neck Neoplasms 101 Brain Neoplasms 101 Recurrence 100 Leukemia 97 Leukemia, Lymphocytic, Chronic, B-Cell 96 Precursor Cell Lymphoblastic Leukemia-Lymphoma 90 Glioblastoma 85 Lymphoma, Non-Hodgkin 83 Colonic Neoplasms 79 Squamous Cell Carcinoma of Head and Neck 76 Lymphoma, Follicular 76 Carcinoma, Renal Cell 75 Lymphoma, Large B-Cell, Diffuse 71 Hematologic Neoplasms 69 Sarcoma 60 Stomach Neoplasms 58

Interventions

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Withdrawn × von Hippel-Lindau Disease × Clear all

NCT06554730 2024-11-29

MK-6482-026

Merck Sharp & Dohme LLC

von Hippel-Lindau Disease

Data powered by HemOnc (CC BY 4.0) Colophon ⚡